Cascade Financial Partners’s FibroBiologics FBLG Stock Holding History

Cascade Financial Partners’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Buy	108,828 +92,400	+562%	+$107K	0.01%	275
2026 Q1	$21.7K	Buy	16,428 +699	+4%	+$4.16K	﹤0.01%	263
2025 Q4	$70.7K	Buy	15,729 +825	+6%	+$5.81K	0.01%	269
2025 Q3	$163K	Buy	14,904 +375	+3%	+$4.49K	0.02%	258
2025 Q2	$181K	Buy	14,529 +1,525	+12%	+$27.5K	0.02%	256
2025 Q1	$234K	Sell	13,004 -1,126	-8%	-$32.2K	0.03%	219
2024 Q4	$565K	Sell	14,130 -1,000	-7%	-$53.7K	0.07%	132
2024 Q3	$871K	Sell	15,130 -623	-4%	-$41.4K	0.11%	105
2024 Q2	$1.57M	Buy	+15,753	New	+$3M	0.21%	73

Other funds holding FBLG

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cascade Financial Partners's FBLG Position: Q2 2026 in Review

Cascade Financial Partners increased its FibroBiologics (FBLG) stake by 562% in Q2 2026, buying an estimated $107K and bringing the position to 108,828 shares worth $103K. The position accounts for 0.01% of the portfolio, ranked #275.

Cascade Financial Partners first reported a position in FBLG in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.57M in Q2 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

Cascade Financial Partners held 108,828 shares of FibroBiologics worth $103K as of Q2 2026.
Cascade Financial Partners bought 92,400 FibroBiologics shares in Q2 2026, an estimated $107K.
FibroBiologics made up 0.01% of Cascade Financial Partners's portfolio in Q2 2026, its #275 holding.
Cascade Financial Partners first reported a position in FibroBiologics in Q2 2024 and has held it in 9 quarters since.
Cascade Financial Partners's FibroBiologics position peaked at $1.57M in Q2 2024.
16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Cascade Financial Partners's 13F filing for Q2 2026, filed 4 Aug 2026.